KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:开放图源暂不可得 入排置信度 0.98

Neoadjuvant Chemotherapy vs Upfront Surgery in Patients With Locally Advanced Colon Cancer: A Randomized Clinical Trial.

Lars Henrik Jensen, Monica Kjaer, Laura Vittrup Diness, Niels Henrik Hollânder, Hans Bjarke Rahr, Frank Pfeffer, Finn Ole Larsen, Jan Lindebjerg, Søren Rafael Rafaelsen, Torben Frøstrup Hansen, Signe Timm, Inger Marie Løes, Ismail Gögenur, Daniela Zitnjak, Fahimeh Andersen, Lone Nørgård Petersen, Elinor Bexe Lindskog, Laurids Østergaard Poulsen, Olav Dahl

JAMA Surg 161(5) 450-458

PMID41779406
PMCIDPMC12961601
DOI10.1001/jamasurg.2026.0085
发表日期2026-03-04
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。
摘要

摘要

IMPORTANCE: Locally advanced colon cancer carries a high risk of recurrence. Neoadjuvant chemotherapy has been proposed to improve outcomes, but evidence from phase III trials remains limited. OBJECTIVE: To determine whether neoadjuvant chemotherapy improves disease-free survival (DFS) compared with upfront surgery in patients with locally advanced colon cancer. DESIGN, SETTING, AND PARTICIPANTS: This randomized, open-label, phase III clinical trial conducted from October 14, 2013, to November 27, 2020, with follow-up up to 3 years for DFS took place at 9 hospitals in Denmark, Norway, and Sweden. A total of 250 patients with locally advanced colon cancer staged by computed tomography, Eastern Cooperative Oncology Group performance status 0 to 2, and no distant metastases were enrolled. These data were analyzed from January 2024 to October 2024. INTERVENTIONS: Patients were randomized 1:1 to upfront surgery followed by adjuvant chemotherapy as indicated (n = 122) or 3 cycles of neoadjuvant capecitabine and oxaliplatin followed by surgery and adjuvant chemotherapy if indicated (n = 126). MAIN OUTCOMES AND MEASURES: The primary end point was DFS. Secondary end points included surgical and pathological outcomes, adjuvant chemotherapy use, adverse events, quality of life, and exploratory analysis by mismatch repair (MMR) status. RESULTS: A total of 248 patients were eligible and included in analyses (median age, 66 [min-max, 24-84] years; 111 women [45%] and 137 men [55%]). At 3 years, DFS was 87% in the upfront surgery arm and 83% in the neoadjuvant arm (P = .36). Neoadjuvant chemotherapy was feasible and safe, achieved tumor downstaging, and reduced the proportion of patients meeting criteria for adjuvant chemotherapy (upfront surgery 73% vs neoadjuvant group 59%; P = .02). Exploratory analyses suggested variation by MMR status, with DFS estimates higher after upfront surgery in patients with MMR-deficient tumors. Postoperative complications, adverse event profiles, and quality of life were comparable between groups. CONCLUSIONS AND RELEVANCE: Neoadjuvant chemotherapy did not improve DFS compared with upfront surgery, establishing the NeoCol trial as negative. However, feasibility, safety, downstaging effects, reduced adjuvant chemotherapy use, and MMR subgroup findings add to evidence from other randomized trials supporting further evaluation of this strategy in individualized management of locally advanced colon cancer. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01918527.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。